Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease
at the MDS 2025 Conference

Lille, September 22, 2025 – InBrain Pharma, a company specialized in the brain infusion of therapeutic agents against neurodegenerative diseases, announced that the long-term follow-up data (at 4.5 years) from its Phase I/II DIVE-I study will be presented at the International Conference of Parkinson’s Disease and Movement Disorders 2025, taking place October 5–9 in Honolulu, Hawaii.

The oral presentation will be delivered by Professor David Devos, co-founder and scientific advisor of InBrain Pharma, on Wednesday, October 8 at 12:00 pm (HAST). An e-poster presenting these additional study results will also be available.

These long-term results confirm the excellent safety profile of the continuous intracerebroventricular infusion of A-dopamine in advanced parkinsonians refractory to L-dopa and also show a sustainable effect on motor control over time. This additional data on top of the results published in January 2025 in Nature Medicine1, illustrates how much A-dopamine will be a medical practice and life changing drug for Parkinson’s disease management. The DIVE-1 trial, having represented a major milestone for InBrain Pharma and the advanced Parkinson’s disease patient community will be fully completed on September 30, 2025.

Abstract Title:                            Intracerebroventricular administration of anaerobic dopamine in Parkinson’s disease patients with L-dopa-related complications
Abstract Number:                      LBA 16
OPP Session Number:              OPP12
OPP Session Title:                      LBA: Clinical Trials
Presentation Date:                    Wednesday, October 8
Session Time:                               12:00 pm – 1:00 pm (HAST)
Room:                                              312
Presentation Order:                   5

Press contact: Florence Portejoie, FP2COM, +33 6 07 76 82 83, fportejoie@fp2com.fr

About InBrain Pharma

InBrain Pharma is a pioneer in personalized medicines for neurology, developing a brain infused A-dopamine (an anaerobic formulation of dopamine) for patients with advanced Parkinson’s disease. Founded in 2018, the company holds an exclusive worldwide license from SATT Nord for the patent covering this breakthrough therapeutic approach, based on the research of Prof. David Devos and Prof. Caroline Moreau, from the University of Lille, INSERM UMR-S 1172 (Lille Neuroscience & Cognition), and Lille University Hospital. In May 2025, InBrain Pharma secured €1.8 million in funding for its “PERCEPAR” project under France 2030’s “First Factory” initiative, aimed at establishing and developing GMP-compliant A-dopamine production. In July 2025, InBrain Pharma received a positive opinion from the EMA to advance A-dopamine to Phase III and secured support from France Parkinson through its investment in the company. https://www.inbrainpharma.fr


1 Link to Nature Medecine’s article :https://doi.org/10.1038/s41591-024-03428-2

Attachment


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.